Dr. Kadia was president and CEO of EAG Laboratories, a global scientific services company providing analytical testing and consulting solutions, which was acquired by Eurofins Scientific in December 2017. He continued to serve as the CEO of EAG laboratories until December 2018. Prior to EAG Laboratories, Dr. Kadia served in several senior roles including the president of Life Sciences Division at Life Technologies Corporation at the time of its acquisition by Thermo Fisher Scientific in February 2014. Prior to Life Technologies, he was a management consultant at McKinsey & Company in the healthcare practice, assisting global medical device companies, and major healthcare providers.
Dr. Kadia earned a B.E. in electronics and telecommunications from Gujarat University in India, an M.S. in biomedical engineering from Rutgers University, and a Ph.D. in biomedical engineering from Johns Hopkins University. He is currently a board member of ALS Limited (ASX:ALQ), Applied Technical Services (ATS), BioSkryb Genomics, Isoplexis Corporation and NuVasive (NSDQ:NUVA). Dr. Kadia’s experience also includes prior public company board service as a director of Volcano Corporation, Newport Corporation, and Horizon Discovery Group plc. (LSE: HZD). In addition to corporate boards, Dr. Kadia serves on the advisory boards of various academic institutions, including Scripps Research Institute.
Dr. Berke’s career has spanned over 25 years in the practice and management of innovation to bring new technologies from lab to market. As a bench scientist and R&D director, he worked at Polaroid Corporation and Hygeia Sciences in the development of photographic and clinical products for both consumer and professional markets – he is an inventor on 6 US patents. He served as a Partner at Integral/Analysis Group, a consulting firm focusing on the management of innovation and growth strategy for clients in healthcare and consumer products. He has been an active private equity investor as a member of Angel Healthcare Investors LLC and is a founder of Mass Medical Angels. He has served on the boards of Quosa [research literature management software], Kasalis [robotics], Combinent [women’s health], Infobionic [cardiac monitoring], Annovation [anesthestic agent] and currently sits on the board of Syntimmune [immunotherapy], QPID Health [bioinformatics], LifeImage [diagnostic image sharing], Sebacia [dermatology therapy] and the Sudanese Education Fund [philanthropy].
Dr. Berke holds an AB degree from Cornell University and received his PhD in Organic Chemistry from the University of California at Berkeley. He also holds an appointment as Lecturer in the MIT Sloan School of Management teaching various courses on the topic of biomedical enterprise.
Dr. Hong joined RiverVest in 2016 and focuses on both biopharmaceutical and medical device opportunities, contributing to the formation, development, and strategic direction of RiverVest portfolio companies. Currently, she serves as a member of the Board of Directors at Scout Bio, Inc., Bluejay Therapeutics, and Biolinq, Inc. Dr. Hong formerly was a member of the Board of Directors at Xilio Therapeutics (NASDAQ: XLO).
Previously, Dr. Hong was a principal with BioMed Ventures, where she originated and managed successful investments in therapeutics, diagnostics, and medical devices. Prior to BioMed, she was an investment professional at Forward Ventures and served as an advisor to biotech and pharmaceutical companies entering new areas of research. She started her career as a scientist at Phenomix, a venture-backed discovery biotech company in San Diego. She trained in the areas of immunology and oncology, earning a B.S. with honors in Biology from the California Institute of Technology and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She conducted postdoctoral training at the University of California, San Francisco, as a fellow of the Leukemia & Lymphoma Society.
